Global Human Vaccines Strategic Business Report 2018: Analysis & Forecast 2016-2024 - Market Trends & Issues
DUBLIN, Dec. 7, 2018 /PRNewswire/ --
The "Human Vaccines - Global Strategic Business Reports" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.
This report analyzes the worldwide markets for Human Vaccines by the following Product Segments:
-- Pediatric Vaccines -- Adult Vaccines
Company profiles are primarily based on public domain information including company URLs.
The report profiles 66 companies including many key and niche players such as:
-- ALK -- Abell A/S (Denmark) -- Altimmune, Inc. (US) -- Bavarian Nordic A/S (Denmark) -- BiondVax Pharmaceuticals Ltd. (Israel) -- Bharat Biotech International Limited (India) -- GlaxoSmithKline Plc. (UK) -- Hualan Biological Engineering Inc. (China) -- Janssen Pharmaceuticals, Inc. (US) -- MedImmune (US) -- Merck & Co., Inc. (US) -- Pfizer Inc. (US) -- Sanofi Pasteur SA (France) -- Serum Institute of India Pvt. Ltd. (India) -- Shanghai BravoBio Co., Ltd. (China) -- Seqirus (UK) -- SK Chemicals Co., Ltd. (Korea) -- Takeda Pharmaceutical Company Limited (Japan) -- Zydus Cadila (India)
Key Topics Covered
1. MARKET OVERVIEW & OUTLOOK
-- Human Vaccines: A Prelude -- Human Vaccines Market -- A Snapshot -- Market Dynamics -- Growth Drivers in a Capsule -- Developed World: The Key Markets -- Emerging Markets: The Future Growth Area -- Vaccine Pricing: The Developed -- Developing Divide
2. MARKET TRENDS & ISSUES
-- Prophylactic Pediatric Vaccines -- A Mature Market -- Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers -- Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective Vaccines -- Novel Vaccines against Emerging Infectious Diseases -- Ongoing Developments for a Vaccine against Zika Virus -- Sanofi's Dengue Vaccine First-to-Market -- Pipeline & Marketed Dengue Vaccine: 2016 -- Computational Tools Come to Aid in Development of Ebola Vaccines -- Vaccine for AIDS -- Ongoing Research for HIV Vaccine & Commercial Pipeline -- List of Clinical Trial (Phase II) AIDS Vaccines: 2015 -- Staggering Global Statistics of AIDS -- Opportunity Indicator -- Vaccination-Autism Link and Other Safety Concerns Thwarted -- Threat of Pandemic Rejuvenates Vaccine Market -- Influenza Vaccines on a Growing Spree -- Influenza Vaccines on the Current Market: 2016 -- H1N1 Vaccines Hit the Market in August 2009 -- H1N1 Influenza Vaccines and Manufacturers -- Influenza Market Faces Several Challenges -- Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market -- Unmet Demand for TB Vaccine -- Key TB Vaccine Candidates in the Pipeline: 2016 -- Need for a Human Vaccine for Leishmaniasis -- Economic Factors Hamper Optimal Vaccine Development and Delivery -- Increasing Need for Vaccine Promotion in the Developing Regions -- Changing Vaccine Needs -- Religious Concerns over Immunizing Young Girls against Human Papillomavirus -- Changing Travel Patterns Increase Demand for Hepatitis B Vaccine -- DNA Vaccines: Engineering Growth -- Noninjectable Vaccines: Gain without Pain -- Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines -- Conjugate Vaccines: A Technological Innovation -- Hib Vaccines on the Market: 2016 -- Growing Pricing Pressure -- A Major Market Deterrent -- Safety Issues Come to the Fore -- BioWarfare: Threat Perception and Preparedness -- Overview of Potential Bio-Terrorist Agents -- Smallpox (Variola Major) -- Anthrax (Bacillus Anthracis) -- Plague (Yersinia Pestis) -- Botulism (Clostridium Botulinum) -- Tularemia (Francisella Tularensis) -- Tackling Cold Chain Issues -- Trade Statistics
3. COMPETITIVE LANDSCAPE
-- Pfizer Scores Big with Prevnar -- Trumenba Shows Promise in Phase III Clinical Trials -- GSK Takes Big Leap into the Meningococcal Vaccine Market -- Acquired Products Strengthen GSK's Vaccines Sales -- The Potential for MenABCWY Vaccine -- Sanofi Works on Production Issues to Boost Sales -- New Vaccines to Enhance Prospects for Sanofi -- Sanofi's Human Vaccine R&D Pipeline -- Weaker Sales Drive Merck and Sanofi's European JV Split -- Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market
4. PRODUCT OVERVIEW
5. CLINICAL TRIALS IN THE VACCINES MARKET
-- Inovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA Vaccine -- Takeda Begins Phase2b Trial for World's First Norovirus Vaccine -- Bavarian Nordic Announces Positive Results from Phase 1 Trial of RSV Vaccine -- Investigational Vaccine for P.vivax Malaria Enters Human Trials -- Valneva Reports Postive Phase 2 Results for Vaccine Candidate against C.difficile -- Novavax Announces Positive Phase 2 Clinical Trial Results for RSV-F Protein Vaccine -- Vical Reports Postive Preclinical Data for CyMVectin CMV vaccine -- Profectus BioSciences Receives HHS Contract to Accelerate Ebola Vaccine Candidate into Clinical Studies -- Inovio and GeneOne to Advance Ebola Vaccine into Phase 1 Trial
6. PRODUCT LAUNCHES/APPROVALS
-- FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok -- Sanofi's Dengue Vaccine Approved in Costa Rica -- GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line -- FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine -- China Launches HFMD Vaccine -- Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection -- Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection -- WHO Accepts Merck's Investigational Ebola Vaccine Application for Review -- Sanofi's Dengvaxia Receives Marketing Authorization in Mexico -- SK Chemicals Launches Influenza Vaccine SKYCellflu -- Sanofi Pasteur Ships First Doses of Fluzone for the US Market -- Bharat Biotech Launches Made-in-India ROTAVAC Vaccine
7. RECENT INDUSTRY ACTIVITY
-- WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13 -- Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility -- Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government -- Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines -- WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue -- Kaketsuken to Sell Vaccines Business to Astellas -- Sanofi and Merck End Joint Venture on Vaccines -- GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine -- Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA -- Bavarian Nordic Enters into License Agreement with Janssen -- CSL Rebrands Influenza Vaccines Business as Seqirus -- MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D -- GlaxoSmithKline Acquires Novartis' Vaccines Business -- Vaxin Changes Name to Altimmune -- Takeda Expands Commercialization Agreement with Nanotherapeutics -- MedImmune Enters Into License Agreement with Inovio Pharmaceuticals -- CSL Completes Acquisition of Novartis' Influenza Vaccines Business -- Pfizer to Acquire Meningitis Vaccines from GSK -- Pfizer Stops Prevnar Vaccine Sales in China After Government Fails to Renew License
8. FOCUS ON SELECT PLAYERS
9. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 63 (including Divisions/Subsidiaries 72)
The United States (22)
Canada (1)
Japan (5)
Europe (14)
-- France (3) -- Germany (2) -- The United Kingdom (2) -- Spain (1) -- Rest of Europe (6)
Asia-Pacific (Excluding Japan) (28)
Latin America (1)
Middle East (1)
For more information about this report visit https://www.researchandmarkets.com/research/xvzs5q/global_human?w=5
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-human-vaccines-strategic-business-report-2018-analysis--forecast-2016-2024---market-trends--issues-300761825.html
SOURCE Research and Markets